Pricing Log in Create free account

Aclaris Therapeutics, Inc. (ACRS) vs Nuvectis Pharma, Inc. (NVCT)

Aclaris Therapeutics, Inc. and Nuvectis Pharma, Inc. are both Biotechnology companies. Aclaris Therapeutics, Inc. and Nuvectis Pharma, Inc. are of similar size ($579.8M and $559.5M). Nuvectis Pharma, Inc. has the higher net margin (0.00% vs −1,244.1%) and the higher return on invested capital (0.00% vs −107.7%). Across the 12 metrics below, Nuvectis Pharma, Inc. leads on 8 and Aclaris Therapeutics, Inc. on 4.

Valuation

Metric ACRS NVCT Biotechnology median
P/E n/m n/m 10.60
P/S 90.59 n/m 9.40
P/B 3.48 4.84 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 74.41 n/m 9.02
Earnings yield (14.95%) (9.08%) (32.88%)
Free cash flow yield (12.99%) (6.57%) (23.13%)

Profitability

Metric ACRS NVCT Biotechnology median
Gross margin 0.00% — 68.51%
Operating margin (1,413.97%) 0.00% 0.00%
Net margin (1,244.09%) 0.00% 0.00%
Free cash flow margin (1,176.61%) 0.00% 0.00%
Return on equity (55.51%) (66.98%) (51.96%)
Return on assets (40.66%) (57.20%) (46.06%)
Return on invested capital (107.72%) 0.00% 0.00%

Growth

Metric ACRS NVCT Biotechnology median
Revenue growth (TTM) (59.34%) — 6.76%
EPS growth (last fiscal year) 69.01% (18.92%) 29.88%
Revenue growth, 5-year CAGR 3.84% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACRS NVCT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.09 9.92 4.97
Net debt to EBITDA 1.20 1.15 1.01

Dividend

Metric ACRS NVCT Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ACRS NVCT Biotechnology median
Market cap 559.49m 579.76m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack